|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Ra Pharmaceuticals (2020)
Schwarz Pharma (2006)
Zogenix (2022)
|
|
gptkbp:CEO
|
gptkb:Jean-Christophe_Tellier
|
|
gptkbp:country
|
gptkb:Belgium
|
|
gptkbp:focusArea
|
immunology
neurology
|
|
gptkbp:foundedYear
|
1928
|
|
gptkbp:founder
|
gptkb:Emmanuel_Janssen
|
|
gptkbp:hasResearchCenter
|
gptkb:Braine-l'Alleud,_Belgium
gptkb:Slough,_United_Kingdom
gptkb:Boston,_United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Brussels,_Belgium
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
UCB Pharma
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Jean-Christophe_Tellier
Catherine Moukheibir
Jean-Pierre Kinet
Mark McDade
|
|
gptkbp:listedOn
|
gptkb:BEL_20
|
|
gptkbp:market
|
global
|
|
gptkbp:notableProduct
|
gptkb:Briviact
gptkb:Cimzia
gptkb:Keppra
gptkb:Neupro
gptkb:Vimpat
|
|
gptkbp:numberOfEmployees
|
~8700
|
|
gptkbp:parentCompany
|
gptkb:UCB_S.A.
|
|
gptkbp:revenue
|
€5.5 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:Euronext_Brussels
|
|
gptkbp:stockSymbol
|
gptkb:UCB
|
|
gptkbp:subsidiary
|
UCB Japan
|
|
gptkbp:therapeuticArea
|
gptkb:Parkinson's_disease
gptkb:bone
gptkb:systemic_lupus_erythematosus
gptkb:myasthenia_gravis
gptkb:Crohn's_disease
epilepsy
rare diseases
autoimmune diseases
inflammatory diseases
psoriasis
lupus
rheumatoid arthritis
seizure disorders
axial spondyloarthritis
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.ucb.com/
|
|
gptkbp:bfsParent
|
gptkb:cetirizine
|
|
gptkbp:bfsLayer
|
6
|